NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma

The Neurofibromin 1 (NF1) tumor suppressor gene is mutated in 15-27% of melanoma patients. The overall prognosis of these patients is worse than that of patients with other genetic melanoma subtypes due to a paucity in targeted therapy options for this melanoma subtype, and its limited response to immunotherapy. Here, we compare NF1 mutant to NF1 wild melanoma using a combined multi-omics approaches of patient-derived short-term cultures (STCs) to identify potential therapeutic targets NF1 mutant and NF1 wild type melanoma short term cultures H3K27ac modifications were compared by Cut and Run to identify gene promoter activities differences